title: [Satisfaction and compliance of ocular hypertensive and glaucoma patients topically treated with a combination therapy].
abstract: OBJECTIVE
  To evaluate satisfaction and compliance in glaucoma and ocular hypertensive patients receiving a fixed combination treatment.
  
  
  METHODS
  After instilling a fixed combination, patients were asked to fill out a questionnaire about their satisfaction and compliance at baseline and 15 days after the onset of new therapy.
  
  
  RESULTS
  1693 glaucoma patients (G) and 621 ocular hypertensive (OHT) patients were included. Mean age was 65.6+/-11.7 years. Onset of disease was 7.2+/-6.6 years and 5.2+/-4.9 years for G and OHT patients, respectively. Insufficient efficacy of the previous topical treatment (monotherapy in 55% of cases) was the main cause for shifting to a fixed combination in 70% of cases. Satisfaction was increased in 15% of the patients and compliance was increased in 25% of the patients.
  
  
  CONCLUSIONS
  Fixed combination provides an easier regimen and therefore encourages better compliance, a key issue in a chronic disease such as glaucoma.
authors.affiliation: Service d'Ophtalmologie, CHU Hôpital Général, Dijon, France. alain.bron@chu-dijon.fr
authors.forename: A
authors.initials: A
authors.lastname: Bron
authors.forename: C
authors.initials: C
authors.lastname: Baudouin
authors.forename: P
authors.initials: P
authors.lastname: Denis
authors.forename: J-P
authors.initials: JP
authors.lastname: Nordmann
authors.forename: J-P
authors.initials: JP
authors.lastname: Renard
authors.forename: J-F
authors.initials: JF
authors.lastname: Rouland
authors.forename: E
authors.initials: E
authors.lastname: Sellem
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000368:Aged; D002257:Carbonic Anhydrase Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D009883:Ophthalmic Solutions; D010349:Patient Compliance; D017060:Patient Satisfaction; D011446:Prospective Studies; D011453:Prostaglandins / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D004338:Drug Combinations; D009883:Ophthalmic Solutions; D011453:Prostaglandins